Singapore, Dec. 18 -- Galux, a South Korean biotech startup pioneering AI-driven protein therapeutics discovery, has signed a research agreement with Boehringer Ingelheim to jointly explore the application of artificial intelligence (AI) in precision protein design for therapeutic development.

The goal is to evaluate how AI can be leveraged to design purpose-specific protein molecules that meet precise scientific and translational needs, where conventional approaches face limitations.

Earlier this year, Galux reached a major milestone in de novo antibody design, successfully discovering novel antibodies with high binding affinity, target specificity and selectivity, structural precision, and stability across multiple therapeutic targets...